Dmitry V Zaretsky Selected Research

Tachycardia (Tachyarrhythmias)

10/2015	Yohimbine is a 5-HT1A agonist in rats in doses exceeding 1 mg/kg.
12/2012	The orexin-1 receptor antagonist SB-334867 decreases sympathetic responses to a moderate dose of methamphetamine and stress.
8/2008	Microinjection of muscimol into the dorsomedial hypothalamus suppresses MDMA-evoked sympathetic and behavioral responses.
11/2007	3,4-Methylenedioxymethamphetamine- and 8-hydroxy-2-di-n-propylamino-tetralin-induced hypothermia: role and location of 5-hydroxytryptamine 1A receptors.
10/2007	Stress- and lipopolysaccharide-induced c-fos expression and nNOS in hypothalamic neurons projecting to medullary raphe in rats: a triple immunofluorescent labeling study.
1/2007	The dorsomedial hypothalamus: a new player in thermoregulation.
6/2006	Stress-induced cardiac stimulation and fever: common hypothalamic origins and brainstem mechanisms.
4/2003	Role of the dorsomedial hypothalamus in thermogenesis and tachycardia caused by microinjection of prostaglandin E2 into the preoptic area in anesthetized rats.
1/2003	Microinjection of muscimol into raphe pallidus suppresses tachycardia associated with air stress in conscious rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dmitry V Zaretsky Research Topics

Disease

9	Hyperthermia 01/2018 - 04/2003
9	Tachycardia (Tachyarrhythmias) 10/2015 - 01/2003
4	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 01/2020
4	Fever (Fevers) 03/2008 - 06/2006
3	Hypertension (High Blood Pressure) 10/2015 - 08/2008
2	Disease Progression 01/2023 - 01/2022
2	Fatigue 01/2018 - 01/2014
2	Hypothermia 10/2015 - 11/2007
1	Amyloid Plaque 01/2022
1	Cognitive Dysfunction 01/2022
1	Mental Disorders (Mental Disorder) 07/2017
1	Inflammation (Inflammations) 10/2007
1	Infarction (Infarctions) 02/2004

Drug/Important Bio-Agent (IBA)

9	Dimenhydrinate (DMH)FDA LinkGeneric 01/2018 - 04/2003
5	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA 05/2015 - 11/2007
4	Amyloid (Amyloid Fibrils)IBA 01/2023 - 01/2020
3	Amyloid beta-PeptidesIBA 01/2023 - 01/2021
3	MuscimolIBA 01/2007 - 01/2003
2	Peptides (Polypeptides)IBA 01/2022 - 01/2020
2	N- (2- (4- (2- methoxyphenyl)- 1- piperazinyl)ethyl)- N- (2- pyridinyl)cyclohexanecarboxamideIBA 10/2015 - 11/2007
2	Amphetamine (Amfetamine)FDA LinkGeneric 01/2014 - 12/2012
2	GABA-A Receptor AgonistsIBA 01/2007 - 01/2003
1	Biomarkers (Surrogate Marker)IBA 01/2023
1	Ion Channels (Ion Channel)IBA 01/2020
1	Corticotropin-Releasing HormoneIBA 07/2017
1	Yohimbine (Yocon)IBA 10/2015
1	AmphetaminesIBA 10/2014
1	Methamphetamine (Desoxyn)FDA LinkGeneric 04/2014
1	Performance-Enhancing SubstancesIBA 01/2014
1	bicuculline methiodideIBA 03/2008
1	Serotonin (5 Hydroxytryptamine)IBA 11/2007
1	5-HT1A Serotonin ReceptorIBA 11/2007
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2007
1	Fentanyl (Sublimaze)FDA LinkGeneric 01/2007
1	Prostaglandins EIBA 01/2007
1	Dinoprostone (PGE2)FDA Link 04/2003

Therapy/Procedure

1	Aftercare (After-Treatment) 11/2007
1	Induced Hypothermia 11/2007
1	Ligation 02/2004